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time elapsed between metastasis appearance and SBRT, ≤ 2 
metastases and single-organ metastatic site. 
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Purpose/Objective: Literature data suggest that the 
oligometastatic state might exist in NSCLC. Selected patients 
with limited metastatic disease can achieve long-term 
survival when treated with locally ablative therapies as 
Stereotactic Ablative radiotherapy (SABR). 
The aim of this study is the evaluation of toxicity, local 
control and overall survival in NSCLC oligometastatic patients 
underwent SABR for lung lesions after multidisciplinary 
assessment. 
Materials and Methods: SABR was performed in 
oligometastatic patients with controlled primary tumor, long 
interval time from the first diagnoses (greater than 6-12 
months), adequate pulmonary function, and number of 
metastatic sites ≤ 5. All patients were discussed at 
multidisciplinary team. According to site and maximum 
diameter of the lung lesion, we adopted the following dose 
prescription: 60 Gy in 3 fractions for peripheral lesions with 
diameter ≤ 2 cm, 48 Gy in 4 fractions for peripheral lesions 
(diameter > 2cm and ≤ 5 cm) and 60 Gy in 8 fractions for 
central lesions. Radiological response was defined according 
to RECIST criteria. Toxicity was recorded according to the 
Common Toxicity Criteria (CTC) version 4.0. 
Results: Between October 2010 and March 2014, 65 NSCLC 
patients for 89 lung lesions were treated at our Institution. 
Radiological response was obtained in most of patients. No 
pulmonary toxicity G3-G4, chest pain or rib fracture 
occurred. The local control at 1 and 2 years was 98% and 87% 
respectively. The median follow up was 24 months (range 6-
40 months). Overall Survival (OS) at 1, 2 years was 77% and 
51% respectively. 
Conclusions: SABR is well tolerated with good radiological 
response and optimal toxicity profile. Discussion within a 
multidisciplinary team is crucial to identify the 
oligometastatic patients could really benefit from ablative 
local therapy.  
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Purpose/Objective: Daily low dose concurrent 
chemoradiation with cisplatin is the standard treatment in 
our institute for locally advanced non-small cell lung cancer 
(NSCLC). However, some patients experiencing renal toxicity 
are not able to receive all cisplatin gifts. Prior to 2011 only 
patients with a decline in renal function were therefore pre-
hydrated with saline prior to treatment in order to reduce 
this toxicity. Since 2011 daily pre-hydration (PH+) has become 
standard practice for all low-dose cisplatin chemoradiation 
patients treated for NSCLC. Renal toxicity is reduced as 
expected but unexpectedly grade 2 or higher acute 
oesophagus toxicity was also reduced from 62% to 34%1. This 
led us to question if there could also be an effect on the 
efficacy of the treatment. The aim of this study was 
therefore to evaluate the effect of pre-hydration on 
progression free survival (PFS) in NSCLC patients treated with 
daily low dose cisplatin chemoradiation. 
Materials and Methods: In total 418 locally advanced 
patients treated in the period 2007-2013 were included in 
this retrospective study. All patients received daily low dose 
cisplatin (6mg/m2). The patients were divided into two time 
periods; 2007-2010 without standard pre-hydration (PH-) and 
2011-2013 with PH+ (1 litre of saline 0.9% prior to the 
administration of a bolus injection of cisplatin). All patients 
received radiotherapy with a prescribed dose of 24 x 2.75 Gy, 
1-2hour after cisplatin injection. Patient and treatment 
characteristics were collected and evaluated. Median follow-
up, PFS and overall survival (OS) were analysed using the log-
rank test and Cox regression. 
Results: The median OS for PH- vs PH+ was 25 and 22 months, 
respectively (p=0.53) with a median follow up of 56 and 20 
months. The median PFS for PH- vs PH+ was 14 and 11 months 
respectively (p=0.11, see figure 1). There was, however, also 
a significant difference in the median GTV of 100 cc in the 
PH- and 61 cc in the PH+ groups (p<0.05). Therefore 
multivariate Cox regression analysis was performed, in which 
PH+ was associated with a hazard ratio (HR) of 1.24 (CI: 0.98-
1.58; p=0.08) and GTV with a HR=1.008 per 1 cc (CI: 1-1.016; 
p=0.06). 
Conclusions: Prehydration in NSCLC patients treated with 
daily low dose concurrent chemoradiation appears to reduce 
progression free survival. Further research into the effect of 
prehydration on cisplatin kinetics within the patient is 
required. This is currently being investigated in mouse 
models. 




   
 
 
 
 
 
 
